Nucleic acid ligands to integrins

• US 7,094,535 B2
• Filed: 12/18/2001
• Issued: 08/22/2006
• Est. Priority Date: 06/10/1991
• Status: Expired due to Fees

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Sciences Inc.
• Inventors: Janjic, Nebojsa, Gold, Larry, Ruckman, Judy, Stephens, Andrew
• Primary Examiner(s): FORMAN, BETTY J
• Assistant Examiner(s): Zitomer, Stephanie
• Application Number:
  US10/024,997
• Publication Number:
  US 20020150536A1
• Time in Patent Office: 1,708 Days
• Field of Search: 435/6, 514/44, 424/9.2, 536/22.1, 536/23.1, 530/350
• US Class Current: 435/5
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2310/322 2'-R Modification
• CPC Class Codes: C12N 2310/3533 Halogen

Abstract

Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.

Claims

1. A method for detecting a site of deep vein thrombosis in an individual, the method comprising:

(a) providing a nucleic acid ligand to a α

_vβ

₃ or α

_IIbβ

₃ mtegrm dimer, wherein said ligand binds to a nucleic acid binding site in said integrin β

₃ and said nucleic acid ligand conjugated to a radioactive label and wherein said nucleic acid ligand is selected from Table 1, 2 or 3;

(b) administering said nucleic acid ligand to said individual;

(c) detecting the site of said thrombosis by analyzing the localization of said nucleic acid ligand using a radioimaging technique.

2. A clot-detection composition comprising a nucleic acid ligand to a α

_vβ

₃ or α

_IIbβ

₃ integrin and a pharmaceutically-acceptable excipient, wherein said ligand binds to a nucleic acid binding site in said integrin β

₃ and wherein said nucleic acid ligand is selected from Table 1, 2 or 3.